EE200100377A - Imidaso[1,5-a]-pürido[3,2-e]-pürasinoonide kasutamine arstimitena - Google Patents

Imidaso[1,5-a]-pürido[3,2-e]-pürasinoonide kasutamine arstimitena

Info

Publication number
EE200100377A
EE200100377A EEP200100377A EEP200100377A EE200100377A EE 200100377 A EE200100377 A EE 200100377A EE P200100377 A EEP200100377 A EE P200100377A EE P200100377 A EEP200100377 A EE P200100377A EE 200100377 A EE200100377 A EE 200100377A
Authority
EE
Estonia
Prior art keywords
pyrazinones
pyrido
imidazo
medicines
Prior art date
Application number
EEP200100377A
Other languages
English (en)
Estonian (et)
Inventor
H�Fgen Norbert
Szelenyi Stefan
Degenhard Marx
Egerland Ute
Original Assignee
Arzneimittelwerk Dresden Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE1999102082 external-priority patent/DE19902082A1/de
Priority claimed from DE1999161302 external-priority patent/DE19961302A1/de
Application filed by Arzneimittelwerk Dresden Gmbh filed Critical Arzneimittelwerk Dresden Gmbh
Publication of EE200100377A publication Critical patent/EE200100377A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
EEP200100377A 1999-01-20 2000-01-14 Imidaso[1,5-a]-pürido[3,2-e]-pürasinoonide kasutamine arstimitena EE200100377A (et)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE1999102082 DE19902082A1 (de) 1999-01-20 1999-01-20 Verwendung von Imidazo[1,5-a]-pyrido[3,2-e]-pyrazinonen als Inhibitoren der Phosphodiesterase 5 zur Therapie von erectiler Dysfunktion und Verfahren zu deren Herstellung
DE1999161302 DE19961302A1 (de) 1999-12-18 1999-12-18 Verwendung von Imidazo(1,5-a)-pyrido(3,2-e)-pyrazinonen als duale Inhibitoren der Phosphodiesterase 5 und der Phosphodiesterase 3 zur Therapie der Herzinsuffizienz, von pulmonaler Hypertonie und Gefäßerkrankungen, die mit einer Minderdurchblutung einhergehen
PCT/EP2000/000260 WO2000043392A2 (de) 1999-01-20 2000-01-14 Verwendung von imidazo[1,5-a]-pyrido[3,2-e]-pyrazinonen als arzneimittel

Publications (1)

Publication Number Publication Date
EE200100377A true EE200100377A (et) 2002-10-15

Family

ID=26051406

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200100377A EE200100377A (et) 1999-01-20 2000-01-14 Imidaso[1,5-a]-pürido[3,2-e]-pürasinoonide kasutamine arstimitena

Country Status (23)

Country Link
EP (1) EP1144410A2 (zh)
JP (1) JP2002535330A (zh)
KR (1) KR20010101603A (zh)
CN (1) CN1344268A (zh)
AR (1) AR022318A1 (zh)
AU (1) AU2291200A (zh)
BG (1) BG105714A (zh)
BR (1) BR0007613A (zh)
CA (1) CA2296224A1 (zh)
CO (1) CO5190700A1 (zh)
CZ (1) CZ20012627A3 (zh)
EA (1) EA200100792A1 (zh)
EE (1) EE200100377A (zh)
HU (1) HUP0105132A3 (zh)
ID (1) ID29790A (zh)
IL (1) IL144156A0 (zh)
IS (1) IS5987A (zh)
LT (1) LT2001078A (zh)
LV (1) LV12793B (zh)
NO (1) NO20013334L (zh)
SK (1) SK10322001A3 (zh)
TR (1) TR200102121T2 (zh)
WO (1) WO2000043392A2 (zh)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6548490B1 (en) * 1997-10-28 2003-04-15 Vivus, Inc. Transmucosal administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction
US6403597B1 (en) 1997-10-28 2002-06-11 Vivus, Inc. Administration of phosphodiesterase inhibitors for the treatment of premature ejaculation
WO2003051346A2 (en) * 2001-12-17 2003-06-26 Altana Pharma Ag Use of selective pde5 inhibitors for treating partial and global respiratory failure
FR2835741B1 (fr) * 2002-02-12 2006-05-05 Oreal Nouveaux coupleurs 6-alcoxy-2,3-diaminopyridine utiles pour la teinture des fibres keratiniques
US6916345B2 (en) 2002-02-12 2005-07-12 L'oreal S.A. 6-alkoxy-2,3-diaminopyridine couplers for dyeing keratin fibres
DE10325813B4 (de) 2003-06-06 2007-12-20 Universitätsklinikum Freiburg Prophylaxe und/oder Therapie bei der portalen Hypertonie
AU2005277384B2 (en) * 2004-08-17 2011-11-17 The Johns Hopkins University PDE5 inhibitor compositions and methods for treating cardiac indications
EP2103613B1 (en) * 2006-12-13 2016-02-17 ASKA Pharmaceutical Co., Ltd. Quinoxaline derivative
US20090143361A1 (en) * 2007-11-30 2009-06-04 Elbion Gmbh Pyrido[3,2-E]Pyrazines, Process For Preparing The Same, And Their Use As Inhibitors Of Phosphodiesterase 10
AU2008329775A1 (en) 2007-11-30 2009-06-04 Biotie Therapies Gmbh Aryl and heteroaryl fused imidazo[1,5-a]pyrazines as inhibitors of phosphodiesterase 10
CA2886885C (en) 2011-10-10 2019-07-16 H. Lundbeck A/S Pde9i with imidazo pyrazinone backbone
US9434733B2 (en) 2012-01-26 2016-09-06 H. Lundbeck A/S PDE9 inhibitors with imidazo triazinone backbone
JP5842640B2 (ja) * 2012-01-31 2016-01-13 株式会社東洋新薬 ホスホジエステラーゼ３阻害剤
US9938284B2 (en) 2014-08-07 2018-04-10 Intra-Cellular Therapies, Inc. Organic compounds
US10005789B2 (en) 2014-08-07 2018-06-26 Intra-Cellular Therapies, Inc. Organic compounds
SI3865484T1 (sl) 2015-07-07 2024-05-31 H. Lundbeck A/S Zaviralec pde9 z imidazo pirazinonsko hrbtenico za zdravljenje perifernih bolezni
JP2021526134A (ja) 2018-05-25 2021-09-30 イマラ インク． ６−［（３Ｓ，４Ｓ）−４−メチル−ｌ−（ピリミジン−２−イルメチル）ピロリジン−３−イル］−３−テトラヒドロピラン−４−イル−７Ｈ−イミダゾ［ｌ，５−Ａ］ピラジン−８−オンの一水和物および結晶形態

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5055465A (en) * 1989-05-31 1991-10-08 Berlex Laboratories, Inc. Imidazoquinoxalinones, their aza analogs and process for their preparation
DE19510965A1 (de) * 1995-03-24 1996-09-26 Asta Medica Ag Neue Pyrido/3,2-e/pyrazinone mit antiasthmatischer Wirksamkeit und Verfahren zu deren Herstellung

Also Published As

Publication number Publication date
CO5190700A1 (es) 2002-08-29
WO2000043392A2 (de) 2000-07-27
JP2002535330A (ja) 2002-10-22
IL144156A0 (en) 2002-05-23
IS5987A (is) 2001-06-29
KR20010101603A (ko) 2001-11-14
NO20013334D0 (no) 2001-07-05
AR022318A1 (es) 2002-09-04
LT2001078A (en) 2002-08-26
NO20013334L (no) 2001-07-05
SK10322001A3 (sk) 2002-07-02
CZ20012627A3 (cs) 2002-01-16
EP1144410A2 (de) 2001-10-17
ID29790A (id) 2001-10-11
HUP0105132A2 (hu) 2002-05-29
TR200102121T2 (tr) 2002-01-21
CA2296224A1 (en) 2000-07-20
AU2291200A (en) 2000-08-07
CN1344268A (zh) 2002-04-10
LV12793B (lv) 2002-05-20
LV12793A (lv) 2002-02-20
EA200100792A1 (ru) 2002-10-31
HUP0105132A3 (en) 2002-12-28
BG105714A (en) 2002-02-28
BR0007613A (pt) 2001-10-30
WO2000043392A3 (de) 2000-09-28

Similar Documents

Publication Publication Date Title
DE60005850D1 (de) Imidazo[1,2-a]pyridin- und pyrazolo[2,3-a]pyridinderivate
ID29514A (id) 2-ARIL-3-(HETEROARIL)-IMIDAZO [1,2-a]PIRIMIDIN TERSUBSTITUSI, DAN METODE-METODE DAN KOMPOSISI-KOMPOSISI FARMASI YANG TERKAIT
IL191960A (en) History of imidazo [5,1– a] pyridine and pharmaceutical preparations containing them
EE200100377A (et) Imidaso[1,5-a]-pürido[3,2-e]-pürasinoonide kasutamine arstimitena
AU7922900A (en) Thiazole and imidazo (4,5-b) pyridine compounds and their pharmaceutical use
HUP0303350A3 (en) Use of substituted imidazo[1,2-a]pyridine-, imidazo[1,2-a]pyrimidine and imidazo[1,2-a]pyrazine-3-yl-amine derivatives for producing nos-inhibiting pharmaceutical compositions
NO20020391D0 (no) 8-Fenyl-6,9-dihydro-[1,2,4]-triazolo-[3,4-i]-purin-5-on- derivater
HUP0500332A3 (en) Substituted 2-pyrimidinyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one and 7-pyrimidinyl-2,3-dihydroimidazo[1,2-a]pyrimidin-5(1h)-one derivatives, their use and pharmaceutical compositions containing them
MXPA02002898A (es) Pirazolopirimidinas como agentes terapeuticos.
NO20000394L (no) 1,2,4-triazolo[4,3-B]pyrido[3,2-D]pyridazinderivater samt farmasøytiske sammensetninger inneholdende slike
HUP0203503A3 (en) Pyrrolo[2,3-d]pirimidine compounds, pharmaceutical compositions containing them and their use
HUP0402018A3 (en) 5-amino-7h-pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidine derivatives, their use and pharmaceutical compositions containing them
DE60103909D1 (de) 2-pyridinyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-on- und 7-pyridinyl-2,3-dihydroimidazo[1,2-a]pyrimidin-5 1honderivate
HUP0500328A3 (en) Substituted 2-pyridinyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one and 7-pyridinyl-2,3-dihydroimidazo[1,2-a]pyrimidin-5(1h)-one derivatives, their use and pharmaceutical compositions containing them
FR2832711B1 (fr) Derives de triazolo [4,3-a] pyrido [2,3-d] pyrimidin-5-ones, compositions les contenant, procede de preparation et utilisation
IL156536A0 (en) Pyrazolo [3,4-d] pyrimidin-4-one derivatives and pharmaceutical compositions containing the same
NO20013645L (no) Anvendelse av pyridazino[4,5-b]indol-1-acetamid-derivater for fremstilling av medisiner for behandling av sykdommer relatert tildysfunksjon av de perifere benzodiazepinreseptorer
PL366858A1 (en) Use of substituted imidazo[1,2-a]-pyridine compounds as medicaments
NO20013384D0 (no) Imidazo[4,5-c]pyridin-4-on-derivater
HK1036274A1 (en) Imidazo (1,2-a) pyridine derivatives for the treatment of gastrointestinal diseases
SI1560830T1 (sl) Derivati (6,7-dihidro-5H-imidazo(1,2-alfa)imidazol-3-sulfonilamino)-propionamida in njihova uporaba kot inhibitorji interakcije CAM in levkointegrinov
MXPA03008894A (es) Uso de compuestos de imidazo[1,2-a]-piridin-3-il-amidas e imidazo [1,2-a]-piridin-3-il-aminas sustituidas como medicamentos.
NO20016271D0 (no) Fremgangsmåte for fremstilling av substituerte [1,4]diazepino[6,7,1-hi]indol-4-oner
NO20014729L (no) Derivater av pyrimido[6,1-a] isokinolin-4-on
AU2002302503A1 (en) Use of substituted imidazo[1,2-A]-pyridine-3-yl-amide and imidazo[1,2-A]-pyridine-3-yl-amine compounds as medicaments for the treatment of neurodegenerative diseases